Teleflex to focus on showcasing its Intraosseous and Central Vascular Access portfolio featuring chlorhexidine based technologies at GAVeCeLT 2015 – December 1-3, in Milan, Italy

Monday, November 30, 2015

WAYNE, Pa.--(BUSINESS WIRE)-- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies for critical care and surgery, is committed to connecting clinicians with technology in a way that improves clinical practice and advances patient outcomes. Teleflex will attend the GAVeCeLT conference in Milan, Italy on December 1-3, 2015.

GAVeCeLT is an Italian Scientific Group doing research on Long Term Vascular Access. The GAVeCeLT society has played a fundamental role over the years in driving adoption of best practices in vascular access.

The GAVeCeLT society invited Dr. Leonardo Lorente to present a cost analysis study related to the use of antimicrobial catheters. Following his studies issued in 20141,2, he has further documented, in an additional research published in 2015, the ability of the Arrow® Central Venous Catheter (CVC) with ARROWg+ard Blue® Technology to reduce both catheter-related bloodstream infections (CRBSIs) and direct costs associated with treating those infections, even when the infection risk is already low.3 The study was an independent retrospective analysis performed and published by Leonardo Lorente, M.D., Ph.D., and colleagues. Dr. Lorente works in the Department of Critical Care at Hospital Universitario de Canarias, in Tenerife, Spain.

During the event, Teleflex will highlight its range of innovative solutions for intraosseous and central vascular access. This includes the Arrow® EZ-IO® Intraosseous Vascular Access System, the ARROWg+ard Blue Plus® Pressure Injectable CVC and the Arrow® PICC with Chlorag+ard® Technology.

The Arrow® EZ-IO® Intraosseous Vascular Access System from Teleflex is a complete solution for rapid vascular access – whether the emergency responder is facing difficult vascular access challenges or the need for fast intraosseous access for critical situations and life-threatening emergencies. This system is designed to provide the medical professional vascular access to the central circulation within seconds, delivering medications, fluids and blood products to adult and pediatric patients alike.

Chlorag+ard® Technology is the 3rd generation of chlorhexidine-based protective treatment for Arrow® Catheters. The application of Chlorag+ard® Technology uses a proprietary process whereby chlorhexidine is chemically bonded to the catheter surface providing a controlled release. Both the internal and external catheter surfaces are treated with chlorhexidine protection. Chlorag+ard® Technology provides an initial burst of chlorhexidine with a sustained release resulting in antithrombogenic and antimicrobial protection.

Another featured product will be the ARROWg+ard Blue Plus® Pressure Injectable CVC. Many patients who receive a central line will require a CT scan and 100% need protection from infection. So to streamline patient care, the ARROWg+ard Blue Plus® Pressure Injectable CVC performs three vital functions: helping prevent catheter-related blood stream infections, delivering therapy and pressure-injecting contrast for CT.

We invite all participants to our booth during the days to learn about our latest technologies.

About Teleflex Incorporated

Teleflex is a global provider of medical technologies designed to improve the health and quality of people’s lives. We apply purpose driven innovation – a relentless pursuit of identifying unmet clinical needs – to benefit patients and healthcare providers. Our portfolio is diverse, with solutions in the fields of vascular and interventional access, surgical, anesthesia, cardiac care, urology, emergency medicine and respiratory care. Teleflex employees worldwide are united in the understanding that what we do every day makes a difference. For more information, please visit

Teleflex is the home of Arrow®, Deknatel®, Hudson RCI®, LMA®, Pilling®, Rüsch® and Weck® – trusted brands united by a common sense of purpose.

Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Any forward-looking statements contained herein are based on our management's current beliefs and expectations, but are subject to a number of risks, uncertainties and changes in circumstances, which may cause actual results or company actions to differ materially from what is expressed or implied by these statements. These risks and uncertainties are identified and described in more detail in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K.

Teleflex, the Teleflex logo, Arrow, ARROWg+ard Blue, ARROWg+ard Blue Plus, Chlorag+ard, Deknatel, EZ-IO, Hudson RCI, LMA, Pilling, Rüsch, and Weck are trademarks of Teleflex Incorporated or its affiliates, in the U.S. and/or other countries. © 2015 Teleflex Incorporated. All rights reserved.


  1. Lorente L, Lecuona M, Jiménez A, et al. Chlorhexidine-silver sulfadiazine-impregnated venous catheters save costs. American Journal of Infection Control, 2014; 42: 321-324.
  2. Lorente L, Lecuona M, Jiménez A, et al. Cost/benefit analysis of chlorhexidine-silver sulfadiazine-impregnated venous catheters for femoral access. American Journal of Infection Control, 2014; 42: 1130-1132.
  3. Lorente L, Lecuona M, Jiménez A, et al. Efficiency of chlorhexidine-silver sulfadiazine-impregnated venous catheters at subclavian sites. American Journal of Infection Control, 2015.